Incidence and correlates of HIV exclusion criteria in cancer clinical trials

Int J Cancer. 2020 Apr 15;146(8):2362-2364. doi: 10.1002/ijc.32800. Epub 2019 Dec 2.

Authors

Ethan B Ludmir¹, Andres F Espinoza², Amit Jethanandani^{1

3}, Timothy A Lin⁴, Walker Mainwaring², Austin B Miller⁵, Prajnan Das¹

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX.
² Baylor College of Medicine, Houston, TX.
³ The University of Tennessee Health Science Center College of Medicine, Memphis, TN.
⁴ The Johns Hopkins University School of Medicine, Baltimore, MD.
⁵ The University of Texas Health Science Center McGovern Medical School, Houston, TX.

PMID: 31746465
DOI: 10.1002/ijc.32800

No abstract available

Publication types

Letter

MeSH terms

Clinical Trials, Phase III as Topic / statistics & numerical data*
HIV Infections / epidemiology*
Humans
Incidence
Neoplasms / epidemiology*
Neoplasms / therapy*
Neoplasms / virology
Patient Selection
Randomized Controlled Trials as Topic / statistics & numerical data*